Daily Medication Pearl: Kazano (Alogliptin and Metformin HCl)

Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Medication Pearl of the Day: Kazano (Alogliptin and Metformin HCl)

Indication: Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).

Insights:

  • Dosing: Kazano should be taken twice daily with food.
  • Dosage forms: Tablets: 12.5 mg alogliptin and 500 mg metformin HCl, 12.5 mg alogliptin and 1000 mg metformin HCl
  • Adverse events: Common adverse reactions reported in ≥4% of patients treated with coadministration of alogliptin with metformin were back pain, diarrhea, headaches, hypertension, nasopharyngitis, upper-respiratory-tract infections, and urinary-tract infections.
  • Mechanism of action: Kazano combines 2 antihyperglycemic agents with complementary and distinct 466 mechanisms of action to improve glycemic control in patients with T2D: alogliptin, a selective inhibitor of DPP-4, and metformin HCl, a member of the biguanide 468 class.
  • Manufacturer: Takeda Pharma

Source:

Label (fda.gov)